explore -WSS

explore

author：entertainment 2025-09-06 03:32:25 - browse：37

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Acelyrin, a rare IPO success, stumbles in its first big test

hotspot

leisure time

WSS

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Novo Nordisk testing Wegovy against alcohol

Telehealth for opioid use disorder is lifesaving

Lilly’s weekly insulin works as well as daily products, new studies show

Oak Street deal isn't the answer to health care's woes

Diverse clinical trials: Why aren’t we there yet?

focus

explore

hotspot

Apple is now the first public company to be valued at $3 trillion

How to make the FDA’s new prescription one

Alkermes shareholders re

Food makers to regulators: Ultra

Medical records are filled with copy

Ripples from Flovent's discontinuation is killing children with asthma

How to save PrEP access — and even expand it

Abbott's new stent may help patients with peripheral artery disease

Peter Hotez and the public health issue of online harassment

Oak Street deal isn't the answer to health care's woes

explore

STAT series 'Denied by AI' wins major journalism prizes

Obesity drug from Roche shows promise in early study

Walmart eyes Medicare Advantage provider ChenMed

STAT series 'Denied by AI' wins major journalism prizes

ALS treatment from Biogen, Ionis fails in study

WuXi Biologics beefs up its lobbying operation

focus

leisure time

knowledge

focus